Table 5.
The 10 metabolic pathways with the highest p-values associated by the IPA software to each of the different antibody microarray sets. The 10 highest p-values of each dataset are given in bold, whereas other p-values and ratios are marked in Italic. The ratio states the number of proteins detected in the microarray versus the total number of proteins being part of the pathway. Data that did not reach significance is marked as n.s.
| 1h | 3h | 6h | 9h | |||||
|---|---|---|---|---|---|---|---|---|
| Pathway | p-value | ratio | p-value | ratio | p-value | ratio | p-value | ratio |
| 1. Molecular Mechanism of Cancer | 3.67 | 17/379 | 1.20 | 32/379 1.33 | 9/379 1.14 | 19/379 | ||
| E-11 | (4.5%) | E-22 | (8.4%) | E-09 | (2.4%) | E-15 | (5.0%) | |
| 6.57 | 9/96 | 3.00 | 19/96 | 2.99 | 5/96 | 1.73 | 15/96 | |
| 2. p53 signaling | E-09 | (9.4%) | E-20 | (19.7%) | E-07 | (5.2%) | E-19 | (15.6%) |
| 3. Glucocorticoid Receptor signaling | 9.70 | 13/295 | 5.01 | 15/295 | n.s. | n.s. | 1.26 | 12/295 |
| E-09 | (4.4%) | E-08 | (5.1%) | 6.31 | 3/73 | E-08 | (4.1%) | |
| 4. Chemokine signaling | 2.44 | 7/73 | 5.74 | 8/73 | E-04 | (4.1%) | n.s. | n.s. |
| 5. Cyclins and Cell Cycle regulation | E-07 | (9.6%) | E-08 | (11.0%) | 1.31 | 5/89 | 2.51 | 10/89 |
| 6.24 | 7/89 | 2.70 | 14/89 | E-07 | (5.6%) | E-12 | (11.2%) | |
| 6. PI3K/AKT signaling | E-07 | (7.9%) | E-14 | (15.7%) | 3.31 | 4/140 | 1.58 | 9/140 |
| 7. ATM signaling | 7.24 | 8/140 | 1.58 | 13/140 | E-05 | (2.9%) | E-08 | (6.4%) |
| 8. VEGF signaling | E-07 | (5.7%) | E-10 | (9.3%) | n.s. | n.s. | 3.94 | 10/54 |
| 9. Apoptosis signaling | 7.59 | 6/54 | 5.01 | 9/54 | 2.14 | 5/99 | E-14 | (18.5%) |
| 10. Death Receptor signaling | E-07 | (11.1%) | E-09 | (16.7%) | E-07 | (5.1%) | 3.47 | 7/99 |
| 8.91 | 7/99 | 5.01 | 12/99 | 6.66 | 3/96 | E-07 | (7.1%) | |
| 11. Chronic Myeloid Leukemia signaling | E-07 | (7.1%) | E-11 | (12.1%) | E-04 | (3.1%) | 4.07 | 7/96 |
| 1.26 | 7/96 | 2.51 | 11/96 | n.s. | n.s. | E-07 | (7.3%) | |
| 12. Pancreatic Adenocarcinoma signaling | E-06 | (7.3%) | E-09 | (11.5%) | 3.16 | 5/105 | n.s. | n.s. |
| 1.58 | 6/95 | 3.51 | 12/65 | E-07 | (4.8%) | 1.71 | 12/105 | |
| E-06 | (9.9%) | E-13 | (18.5%) | 2.29 | 4/119 | E-14 | (11.4%) | |
| 13. PTEN signaling | 2.00 | 7/105 | 1.59 | 15/105 | E-05 | (3.4%) | 7.94 | 10/119 |
| 14. Huntington's Disease signaling | E-06 | (6.7%) | E-14 | (14.3%) | 2.69 | 4/124 | E-11 | (8.4%) |
| 5.01 | 7/119 | 2.00 | 11/119 | E-05 | (3.2%) | n.s. | n.s. | |
| 15. Small Cell Lung Cancer signaling | E-06 | (5.9%) | E-08 | (9.2%) | 2.19 | 5/238 | 1.48 | 14/238 |
| 6.31 | 7/124 | 3.16 | 13/124 | E-05 | (2.1%) | E-12 | (5.9%) | |
| 16. Cell Cycle: G1/S Checkpoint regulation | E-06 | (5.6%) | E-11 | (10.5%) | 7.65 | 5/89 | n.s. | n.s. |
| 1.26 | 8/238 | 7.94 | 16/238 | E-08 | (5.6%) | 1.91 | 7/61 | |
| E-04 | (3.4%) | E-10 | (6.7%) | 8.91 | 3/61 | E-08 | (11.5%) | |
| 17. Glioma signaling | 1.58 | 5/89 | 3.80 | 18/89 | E-05 | (4.9%) | 3.16 | 10/112 |
| 18. GM-CSF signaling | E-04 | (5.6%) | E-09 | (11.2%) | 3.98 | 5/112 | E-11 | (8.9%) |
| 19. IL-8 signaling | n.s. | n.s. | 3.98 | 11/61 | E-07 | (4.5%) | n.s. | n.s. |
| 20. HGF signaling | n.s. | n.s. | E-12 | (18.0%) | 3.16 | 4/67 | n.s. | n.s. |
| 21. Role of NFAT in Cardiac Hypertrophy | n.s. | n.s. | 6.31 | 11/112 | E-06 | (6.0%) | 2.75 | 8/105 |
| n.s. | n.s. | E-09 | (9.8%) | 6.31 | 5/193 | E-08 | (7.6%) | |
| 22. Hereditary Breast Cancer signaling | n.s. | n.s. | n.s. | n.s. | E-06 | (2.6%) | 6.31 | 12/208 |
| n.s. | n.s. | 3.98 | 14/193 | 2.00 | 4/105 | E-11 | (5.8%) | |
| n.s. | n.s. | E-09 | (7.3%) | E-05 | (3.8%) | 2.00 | 10/129 | |
| n.s. | n.s. | n.s. | n.s. | E-10 | (7.8%) | |||
| 7.59 | 10/208 | 1.02 | 3/129 | |||||
| E-06 | (4.8%) | E-03 | (2.3%) | |||||
| 5.25 | 10/129 | |||||||
| E-08 | (7.8%) | |||||||